Clearside Biomedical Files 8-K on Security Holder Vote

TL;DR

Clearside Biomedical held a shareholder vote, details to follow.

AI Summary

Clearside Biomedical, Inc. filed an 8-K on June 20, 2024, to report on the submission of matters to a vote of its security holders. The filing does not contain specific details about the matters voted upon or any outcomes.

Why It Matters

This filing indicates that Clearside Biomedical is engaging its shareholders on important corporate decisions, which could impact the company's future direction and shareholder value.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any new financial information or significant corporate events that would immediately impact risk.

Key Players & Entities

• Clearside Biomedical, Inc. (company) — Registrant
• June 20, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar

Filing Documents

• clsd-20240620.htm (8-K) — 60KB
• 0000950170-24-075603.txt ( ) — 171KB
• clsd-20240620.xsd (EX-101.SCH) — 24KB
• clsd-20240620_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 20, 2024, Clearside Biomedical, Inc. (the " Company ") held its 2024 annual meeting of stockholders (the " Annual Meeting "). At the Annual Meeting, the Company's stockholders considered three proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2024 (the " Proxy Statement "). Of the 74,731,139 shares outstanding as of the record date, 50,056,288 shares, or 67%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. Proposal No. 1 : Election of three nominees to serve as directors until the 2027 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Broker Non-Votes Richard Croarkin 30,202,533 4,445,629 15,408,126 William D. Humphries 30,187,760 4,449,070 15,419,458 Nancy J. Hutson 29,492,996 5,146,798 15,416,494 All nominees were elected. Proposal No. 2 : Approval, on an advisory basis, of the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: Votes For Votes Against Abstained Broker Non-Votes Advisory approval of the compensation paid to the named executive officers 22,811,768 5,237,370 6,599,024 15,408,126 Proposal No. 3 : Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Ernst & Young LLP 45,119,612 4,880,367 56,309

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 20, 2024 CLEARSIDE BIOMEDICAL, INC. By: /s/ Charles A. Deignan Name: Charles A. Deignan Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR